Rankings
▼
Calendar
RYTM Q1 2025 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RYTM
Rhythm Pharmaceuticals, Inc.
$6B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$33M
+25.9% YoY
Gross Profit
$29M
88.8% margin
Operating Income
-$47M
-143.7% margin
Net Income
-$49M
-151.4% margin
EPS (Diluted)
$-0.81
QoQ Revenue Growth
-21.8%
Cash Flow
Operating Cash Flow
-$40M
Free Cash Flow
-$40M
Stock-Based Comp.
$13M
Balance Sheet
Total Assets
$387M
Total Liabilities
$224M
Stockholders' Equity
$163M
Cash & Equivalents
$106M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$33M
$26M
+25.9%
Gross Profit
$29M
$23M
+25.5%
Operating Income
-$47M
-$140M
+66.4%
Net Income
-$49M
-$141M
+65.0%
Revenue Segments
Product
$38M
100%
Geographic Segments
Non-US
$13M
100%
← FY 2025
All Quarters
Q2 2025 →